Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.64 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.64 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.48 |
| ▸ | HTR3B | O95264 | 2/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4935425 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4PIM1PIM3ADRB1 | |
| Hydrochloric Acid SCHEMBL21045786 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4PIM1PIM3ADRB1 | |
| SCHEMBL5658694 | 0.93 | CHRNB2 (0.68) | CHRNB2CHRNA4PIM1PIM3 | |
| SCHEMBL25143036 | 0.89 | CHRNB2 (0.51) | CHRNB2CHRNA4PIM1PIM3ADRB1 | |
| Pivalate SCHEMBL28600103 | 0.85 | CHRNB2 (0.49) | CHRNB2CHRNA4PIM1PIM3ADRB1 | |
| Tert-Butyl Formate SCHEMBL27722336 | 0.83 | CHRNB2 (0.47) | CHRNB2CHRNA4PIM1PIM3ADRB1 | |
| SCHEMBL13779836 | 0.82 | MAPT (0.50) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL3367822 | 0.82 | CHRNB2 (0.47) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL29883782 | 0.82 | MAPT (0.50) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL823334 | 0.81 | MAPT (0.53) | CHRNB2CHRNA4KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504739-A | Novel method for synthesizing palbociclin | 江苏权正检验检测有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119504740-A | New preparation method of palbociclin | 江苏权正检验检测有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-118994194-A | Small molecular compound with IDO1 inhibitory activity and preparation method and application thereof | 新疆医科大学第一附属医院 | 2024-11-22 | — | — | CN | claimed |
| CN-117141062-B | Flame-retardant copper-clad plate and preparation process thereof | 江苏富乐华半导体科技股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-117069663-B | Synthesis method of rebaudinib intermediate V and synthesis method of rebaudinib | 四川维亚本苑生物科技有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-117185761-A | Preparation method of high-compactness flame-retardant gypsum-based fiber board | 泰山石膏（江阴）有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-111995569-B | Preparation method of cyclin-dependent kinase inhibitor intermediate | 成都博腾药业有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-117141062-A | Flame-retardant copper-clad plate and preparation process thereof | 江苏富乐华半导体科技股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-117069663-A | Synthesis method of rebaudinib intermediate V and synthesis method of rebaudinib | 四川维亚本苑生物科技有限公司 | 2023-11-17 | — | — | CN | claimed |
| EP-4126244-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | claimed |
| CN-111995569-A | Preparation method of cyclin-dependent kinase inhibitor intermediate | 成都博腾药业有限公司 | 2020-11-27 | — | — | CN | claimed |
| CN-111574518-A | Pyridine oxide derivative and composition, preparation method and application thereof | 黄泳华 | 2020-08-25 | — | — | CN | claimed |
| CN-111265668-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | claimed |
| EP-1781647-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2007-05-09 | — | — | EP | claimed |
| WO-2006008545-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | WO | claimed |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| EP-4644390-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| WO-2006008545-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005099711-A1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | CHRNB2 4855/4885CHRNA4 4787/4885PIM1 329/4885 |
| US-20080167309-A1 | Pharmaceutical Compounds | CCNO, CDK2, CDK1 | CHRNB2 1268/4885CHRNA4 1874/4885PIM1 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.